Our mission is to develop and market innovative biotechnology products for a better quality of life.

Our success is based on a continuous focus on increasing shareholder value, and upon the contributions of employees who share a common vision of solving health challenges by creating innovative technologies and products.

Transparency, accountability and financial discipline have created trust and sustained support from our investors and partners.

We develop proprietary improved protein-based products to maximise mid- and long-term value creation. At the same time, we generate revenues and built trust through specific, high value, collaborations on protein or cell line improvement with selected partners.

Drug discovery and development is a high-reward, high-risk business. Nautilus can reduce the risks associated with creating new products and increases the chances of success by working primarily on proteins that have validated clinical development pathways, to develop next-generation molecules with improved therapeutic profiles. These include drugs that are currently on the market or in mid-late stage clinical trials.

Our ongoing programs, internal and in partnership, are aimed at developing proteins that are potentially safer and/or more effective than current drugs, and address serious unmet clinical needs.

Nautilus has adopted a highly effective approach to solve the manufacturing inefficiencies and low yield bottlenecks that currently surrounds the manufacture of biological products. Our cell line optimisation technology is used to create stable high yield cell lines for application in the manufacture of vaccines, recombinant proteins and antibodies, for both partners and Nautilus own internal protein improvement programs.